Response to "Comment on sarcopenia and myosteatosis are associated with low survival in patients receiving lenvatinib for unresectable hepatocellular carcinoma".

Luo, Pei-JuiPei-JuiLuoCHIH-HORNG WU2025-05-052025-05-052025-02-1009296646https://scholars.lib.ntu.edu.tw/handle/123456789/728813entrue[SDGs]SDG2[SDGs]SDG3[SDGs]SDG5Response to "Comment on sarcopenia and myosteatosis are associated with low survival in patients receiving lenvatinib for unresectable hepatocellular carcinoma".letter10.1016/j.jfma.2025.02.004399297552-s2.0-86000345347